Treatment Advancements in Newly Diagnosed and Relapsed/Refractory in Multiple Myeloma - Episode 1
Managing Transplant-Eligible NDMM: Current Treatments
Panelists discuss how quadruplet-based induction therapy, including anti-CD38 monoclonal antibodies, is becoming the preferred frontline treatment for transplant-eligible patients with multiple myeloma based on risk stratification.
Risk Stratification and Quadruplet Therapy in Transplant-Eligible Multiple Myeloma
The treatment landscape for transplant-eligible newly diagnosed multiple myeloma has evolved rapidly with the adoption of quadruplet regimens. Experts emphasize the importance of accurate risk stratification to guide therapy, distinguishing between standard-risk and high-risk patients. Determining the appropriate induction regimen hinges on both biological risk and patient-specific factors.
Quadruplet-based therapy, particularly those including anti-CD38 monoclonal antibodies alongside standard backbones such as VRd or KRd, has shown improved response rates and progression-free survival. These regimens are now becoming the standard of care in transplant-eligible patients, supported by multiple clinical studies demonstrating superior outcomes compared to triplet regimens.
For high-risk patients, modifications to the quadruplet approach are considered, such as using carfilzomib instead of bortezomib. Clinicians continue to refine treatment strategies based on ongoing trials, aiming to deepen response and prolong survival while minimizing toxicity.
Related Content:
